LAURIE CLAIR: Open Payments
NPI 1790046548 · JOHNSTON, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$74,191 in 255 payments from 16 companies in 2025. Trend: 2023 $66,655 · 2024 $49,562 · 2025 $74,191
Speaker / faculty: $58,180Travel & lodging: $7,453Food & beverage: $4,885Consulting: $3,561Education: $111
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 56 | $37,296 |
| ABBVIE INC. | 65 | $26,013 |
| E.R. Squibb & Sons, L.L.C. | 37 | $8,987 |
| Otsuka America Pharmaceutical, Inc. | 37 | $611 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $371 |
| Teva Pharmaceuticals USA, Inc. | 12 | $304 |
| Lundbeck LLC | 9 | $149 |
| Janssen Pharmaceuticals, Inc | 4 | $101 |
| MDD US Operations, LLC | 5 | $94 |
| Axsome Therapeutics, Inc. | 3 | $63 |
Products named: FANAPT, VRAYLAR, COBENFY, REXULTI, CAPLYTA, AUSTEDO XR, Qelbree, INVEGA SUSTENNA.
Industry payments across IA — which companies pay providers there.
